Sign up for free newsletter

 

DNA

IBS Capital sells IQuum stake to Roche

IBS Capital has sold its equity investment in IQuum to Roche. 

IBS made its initial capital investment in IQuum in 1999 shortly after the firm was founded and has remained its largest outside investor over the past 15 years. 
 
David Taft, the president of IBS, also served as a director on IQuum's board of directors since 1999.  During this period, IQuum developed groundbreaking technology in molecular diagnostics. 
 
Taft says: "IQuum's Laboratory-in-a-tube (Liat) System will dramatically improve the point of care segment of the diagnostics market and will bring significant benefits to Roche.  In combination with Roche's extensive technological, marketing and financial resources, the Liat system will provide healthcare clinics and hospitals with fast, accurate and simple to use testing for a wide range of medical conditions."


Subscribe to free daily newsletter
MediaWatch WA awards 2015

See interviews and presentation at the Wealth Adviser 2015 awards ceremony, held at Sketch, Mayfair on the 15th May .... »

latestjobs
Leveraged Finance Associate NYC

Mon, 06 Jul 2015 00:00:00 GMT

Consumer Associate Bulge Bracket *Urgent Hire*

Mon, 06 Jul 2015 00:00:00 GMT

VP KDB/Q Developer

Mon, 06 Jul 2015 00:00:00 GMT

events
18 hours 58 min from now - Hong Kong
1 week 5 days from now - Rhode Island
specialreports